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Abstract
Background: The benefit of the coronary collateral circulation (natural bypass network) on survival is well
established. However, data derived from smaller studies indicates that coronary collaterals may increase the risk for
restenosis after percutaneous coronary interventions. The purpose of this systematic review and meta-analysis of
observational studies was to explore the impact of the collateral circulation on the risk for restenosis.
Methods: We searched the MEDLINE, EMBASE and ISI Web of Science databases (2001 to 15 July 2011). Random
effects models were used to calculate summary risk ratios (RR) for restenosis. The primary endpoint was
angiographic restenosis > 50%.
Results: A total of 7 studies enrolling 1,425 subjects were integrated in this analysis. On average across studies, the
presence of a good collateralization was predictive for restenosis (risk ratio (RR) 1.40 (95% CI 1.09 to 1.80); P =
0.009). This risk ratio was consistent in the subgroup analyses where collateralization was assessed with
intracoronary pressure measurements (RR 1.37 (95% CI 1.03 to 1.83); P = 0.038) versus visual assessment (RR 1.41
(95% CI 1.00 to 1.99); P = 0.049). For the subgroup of patients with stable coronary artery disease (CAD), the RR for
restenosis with ‘good collaterals’ was 1.64 (95% CI 1.14 to 2.35) compared to ‘poor collaterals’ (P = 0.008). For
patients with acute myocardial infarction, however, the RR for restenosis with ‘good collateralization’ was only 1.23
(95% CI 0.89 to 1.69); P = 0.212.
Conclusions: The risk of restenosis after percutaneous coronary intervention (PCI) is increased in patients with
good coronary collateralization. Assessment of the coronary collateral circulation before PCI may be useful for risk
stratification and for the choice of antiproliferative measures (drug-eluting stent instead bare-metal stent, cilostazol).
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Background
Coronary collaterals are present in normal and diseased
hearts. This coronary collateral circulation (CCC) has
the potential to alleviate myocardial ischemia [1,2].
T h e r ei ss t r o n ge v i d e n c et h a tt h eC C Ch a sap o s i t i v e
impact on survival [3,4]. However, some data suggested
an increased risk for restenosis following percutaneous
coronary intervention (PCI) in patients with good
collateralization; however, the findings derive from small
studies and have been rather inconsistent [5,6]. The pur-
pose of this systematic review and meta-analysis was to
integrate all available data in order to provide a clearer
understanding of the impact of the coronary collateral
on the risk for restenosis following PCI.
Methods
The study was performed according to the Meta-analysis
Of Observational Studies in Epidemiology (MOOSE)
guidelines for meta-analyses of observational data (Addi-
tional file 1) [7]. Planning and study design was per-
formed by two authors (CS, PM) including creation of an
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any medium, provided the original work is properly cited.electronic database with variables of interest (Microsoft
Excel; Microsoft, Redmond, WA, USA). Primary and sec-
ondary endpoints, variables of interest and search strat-
egy (databases, sources for unpublished data) were
defined in a strategy outline that can be obtained from
the study authors on request.
Search strategy
We searched the EMBASE, PubMed, MEDLINE, BIOS,
International Pharmaceutical Abstracts database, and ISI
Web of Science databases from 1980 to 15 July 2011. In
addition, abstract lists and conference proceedings from
the 2006 to 2010 scientific meetings of the American
College of Cardiology, the European Society of Cardiol-
ogy, the symposium on Transcatheter Cardiovascular
Therapeutics, the American Heart Association, and the
World Congress of Cardiology were searched. We also
considered published review articles, editorials, and inter-
net-based sources of information http://www.tctmd.com,
http://www.theheart.org, http://www.europcronline.com,
http://www.cardiosource.com, and http://www.crtonline.
com to assess potential information on studies of interest.
Reference lists of selected articles were reviewed for other
potentially relevant citations. No language restriction was
applied. Authors of selected studies were contacted to
obtain further information if needed. All prospective stu-
dies reporting on an association between restenosis prob-
ability and coronary collateral circulation were included
in this analysis. Retrospective case-control studies were
not considered. We focused on prospective cohort stu-
dies because our objective was to define the value of col-
laterals as a marker for future restenosis. Furthermore,
we excluded retrospective case-control studies because
we think that matching of cases with controls could
introduce critical bias; and in many cases, collaterals can-
not be assessed accurately in retrospect.
The detailed search syntax used for the Medline data-
base is shown in Additional file 2. The syntax for other
databases was similar, but was adapted where necessary.
Study selection
In a two-step selection process, the titles and abstracts
of all citations were reviewed by two researchers (PM,
CS) to identify potentially relevant studies. In a second
step, the full text of corresponding publications was
reviewed to assess whether the studies met the following
inclusion criteria: association of restenosis risk and the
degree of coronary collateralization (Figure 1).
Data extraction and quality assessment
Relevant information from the articles including baseline
clinical characteristics of the study population and out-
come measures was extracted using the prepared stan-
dardized extraction database (Excel). The quality of each
study was assessed with the Newcastle-Ottawa Scale
(NOS) for assessing the quality of non-randomized stu-
dies in meta-analyses (Table 1) [8]. Based on this scale,
an additional sensitivity analysis of studies with superior
quality was performed (at least seven of eight points).
W ed i dn o tu s et h eq u a l i t ys c o r e sf o rs t u d yw e i g h t i n g
due to the limitations inherent to such an approach [9].
Endpoints
The primary endpoint of this analysis was angiographic
binary restenosis (> 50% restenosis). This dichotomized
endpoint definition was selected because we expected
that most studies report on dichotomized values; classi-
cally, a 50% cut off has been used in angioplasty studies.
This value was mainly based on the experimental work
of Gould et al., demonstrating blunting of the hypere-
mic response at a stenosis degree of 50% [10].
Definitions
Good collateralization was defined differently for the
individual studies. Three studies performed a visual
assessment (Rentrop score) [11] and used a score of ≤ 1
for poor collateralization (no or only faintly visible collat-
erals). In brief, the Rentrop score assigns four degrees of
collateralization depending on the presence and exten-
sion of the collateral filling of coronary epicardial vessels
d u r i n gac o r o n a r ya n g i o g r a m(grade 0 = no collaterals;
grade 1 = side branch filling of the recipient artery with-
out filling of the main epicardial artery; grade 2 = partial
filling of the main epicardial recipient artery; grade 3 =
complete filling of the main epicardial recipient artery).
Four studies based their collateral quantification on intra-
coronary pressure measurements (collateral flow index
(CFI)) [12] (Table 2) and defined poor collateralization as
a CFI < 0.25. The CFI defines the proportion of blood
flow that derives from the collateral circulation in com-
parison to the antegrade blood flow through the main
coronary artery. The CFI is measured with a pressure
sensor tipped coronary guidewire, which is placed in the
distal vessel. The collateral flow index calculation is
based on the occlusion pressure during a 1-minute bal-
loon inflation and the pressure proximal to the balloon
occlusion (aortic pressure). The central venous pressure
is subtracted from these two pressures to correct for the
back pressure: CFI = (occlusion pressure - central venous
pressure) ÷ (systemic pressure - central venous pressure).
Data synthesis and analysis
Data from included studies were combined to estimate the
pooled impact (risk ratio (RR)) of good collateralization
versus poor collateralization. Calculations were based on a
DerSirmonian and Laird random-effects model [13]. This
model assumes that the true effects vary between studies
for unknown reasons. The primary summary measure
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studies [14]. Continuity correction was used when no
event occurred in one group to allow calculation of a RR
[15]. Heterogeneity among trials was quantified with the
Higgins and Thompson I
2 [16]. I
2 can be interpreted as
the percentage of variability due to heterogeneity between
studies rather than sampling error. An I
2 > 50% was con-
siderate as an at least moderate heterogeneity. We present
as our primary results estimates of the average effect
across studies with 95% confidence intervals in brackets.
In addition, we also calculated 95% prediction intervals as
described by Higgins et al. [14]. These intervals predict
the effect that we would potentially expect to see in a new
study. These data are presented in the Sensitivity analysis
section. To assess the effect of moderator variables (study
setting, method of collateral assessment, proportion of
stent use, risk of restenosis in the control groups), a
mixed-effects model was used (meta-regression). For bin-
ary moderator variables, we also present the ratio of risk
ratios, which was calculated with the exponential function
exp (estimated regression coefficient), with the according
95% confidence intervals. Prespecified subgroup analyses
were ‘setting’ (elective PCI versus acute myocardial infarc-
tion (MI)) and ‘collateral assessment method’ (visual ver-
sus CFI). The remainder of the subgroup/meta-regression
analyses were performed post hoc in an exploratory
fashion.
To assess the effect of individual studies on the sum-
mary estimate of effect, we performed an influence ana-
lysis using a jackknife procedure; pooled estimates were
recalculated by omitting one study at a time. We
assessed publication bias visually (funnel plot) and by
Figure 1 Study selection process.
Table 1 Quality assessment of studies according to the Newcastle-Ottawa Scale
Lead
author
Representativeness Control
group
Ascertainment Endpoint not present
at start
Assessment of
outcome
Follow-up
duration
Adequacy
follow-up
Probst * * * * *
Nakae * * * * *
Wahl * * * * * *
Perera * * * * * * *
Jensen * * * * * * *
Lee * * * * * * *
Antoniucci * * * * *
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of intercept) [17,18]. All analyses were performed with
R version 2.10.1 (package ‘meta’) [19].
Results
Description of included studies
A total of 123 articles were reviewed and 7 studies
including 1,425 patients satisfied the predetermined
inclusion criteria (Figure 1) [5,6,20-24]. The study of
Wahl et al. has been published as a retrospective case-
control study [25]. The study focused on patients with
restenosis (case) and compared them to control patients
without restenosis. The data used in this meta-analysis
are based on a reanalysis of the identical cohort but
with dividing patients into a group with ‘good collatera-
lization’ and ‘poor collateralization’, depending on their
CFI (< threshold versus ≥ 0.25), the incidence of reste-
nosis (≥ 50% diameter stenosis) was calculated for the
two groups (unpublished results). Table 2 summarizes
the characteristics of the included studies. All patients
had routine angiographic follow-up.
Restenosis risk
Patients with a good collateralization showed a signifi-
cantly increased risk for restenosis compared to patients
with poor collateralization (RR 1.40 (95% CI 1.09 to
1.80); P = 0.009 (heterogeneity: tau
2 =0 . 0 5 5 ;I
2 =5 2 . 2 %
(95% CI 0% to 79.7%); P = 0.051) (Figure 2).
Investigation of heterogeneity
Analyses stratified by the method of collateral assess-
ment showed very consistent results: good collaterals
were associated with an increased restenosis risk. For
visually assessed collateral assessment (based on Rentrop
scoring) the RR was 1.41 ((95% CI 1.00 to 1.99); P =
0.049 (heterogeneity: tau
2 = 0.059; I
2 = 64.1%, P =
0.062)) and for CFI-based collateral assessment, the cor-
responding RR was 1.37 ((95% CI 1.03 to 1.83); P =
0.038 (heterogeneity: tau
2 = 0.112; I
2 = 56.1%, P =
0.077)) (Figure 3). There was no significant impact of
the assessment method on the risk ratio in the
according meta-regression analysis, the ratio of risk ratio
between ‘visual assessment’ and ‘CFI based assessment’
was 1.02 (95% CI 0.59 to 1.71), P = 0.953.
The results were also very consistent between the two
studies using plain balloon angioplasty (POBA) in all
patients and those two studies using bare metal stents
(BMS) (Table 2). The proportion of BMS used in the
individual studies had no significant effect on the result
neither (meta-regression: slope -0.15 (95% CI -10.83 to
0.54); P = 0.221; the meta-regression slope describes the
impact of the proportion of BMS use on the study effect
size; the log RR decreases on average by -0.15 when all
the patients have a BMS implanted compared to the
situation where none of the patients receives a BMS.
(Additional file 3) Further, no significant effect of the
restenosis risk in the control group (patients with poor
collaterals) on the results was found neither (meta-
regression: slope -2.44 (95% CI -6.54 to 1.66) P =0 . 4 2 5 ) ;
this means that the log RR decreases on average by -2.44
if the restenosis risk in the control group (poor collat-
erals) is 100% compared to the situation where the reste-
nosis risk is 0% (Additional file 4).
However, patients undergoing elective PCI for stable
coronary artery disease (CAD) tended to show a more
pronounced influence of collaterals on the restenosis
risk. The risk ratio for those with good collateralization
was 1.64 (95% CI 1.14 to 2.35); P = 0.008 (heterogeneity:
tau
2 = 0.049; I
2 = 35.9%, P = 0.197)). For patients with
acute myocardial infarction, however, the respective RR
was 1.23 (95% CI 0.89 to 1.69); P = 0.212 (heterogeneity:
tau
2 = 0.049; I
2 = 58.3%, P = 0.091)) (Figure 4). How-
ever, the according meta-regression analysis showed no
statistically significant effect of this variable on the RR,
the ratio of risk ratio between ‘elective PCI’ and ‘acute
MI’ was 1.33 (95% CI 0.82 to 2.16), P = 0.243.
Sensitivity analyses
None of the studies influenced the results to the extent
that the conclusion would have changed; the jackknife
procedure-based sensitivity analysis omitting one study
at a time consistently showed that good collateralization
Table 2 Summary of the characteristics of the included studies
Lead author Year CCC assessment Setting Follow-up (months) PCI type Male (%) Age (years)
Probst 1991 Visually Elective 4 to 7 POBA 100% 79 51
Nakae 1996 Visually Acute MI Mean 5.7 POBA 100% 75 62
Wahl 2000 CFI Elective Mean 17 BMS 43% 74 60.5
Lee 2002 CFI Acute MI 6 BMS 74.3% 73 57
Antoniucci 2002 Visually Acute MI 6 BMS 64% 78 64
Perera 2006 CFI Elective 6 BMS 100% 80 60
Jensen 2007 CFI Elective 9 BMS 100% 75 61
BMS, bare metal stents; CCC, coronary collateral circulation; CFI, collateral flow index (intracoronary wedge-pressure derived collateral assessment); PCI,
percutaneous coronary intervention; POBA, plain balloon angioplasty; Visually, collateral assessment with Rentrop scoring system.
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Specifically, excluding the only unpublished data
included in this analysis (based on Wahl et al. [25]) did
not change the overall RR estimate (RR 1.43 (95% CI
1.07 to 1.91); P = 0.016 (heterogeneity: tau
2 = 0.074; I
2
=6 0 . 1 % ,P = 0.028)). When considering studies with
highest quality only (based on the Newcastle-Ottawa
Scale; at least seven of eight points), the estimate for RR
for restenosis for the group with good collaterals was
very consistent but did not reach statistical significance
(1.47 (95% CI 0.78 to 2.76); P = 0.235 (heterogeneity:
tau
2 <0 . 0 0 1 ;I
2 =0 % ,P = 0.866)); three studies were
considered in this analysis [5,6,24].
The funnel plot was symmetrical (Figure 6) and for-
mal testing did not indicate a relevant ‘small study
effect’ or publication bias (Egger’st e s tP =0 . 3 6 2 ,r a n k
correlation test P = 0.273).
Three studies enrolled patients with acute MI. While
the visual assessment of collaterals should not be altered
and may even be more accurate, because the vessel of
interest is occluded and avoids ‘competitive’ flow via the
native and the collateral vessels, the accuracy of quantita-
tive CFI measurements have been questioned in this
setting [26]. When excluding the one study using CFI
measurements in acute MI [6], the overall result
increases minimally, from RR 1.40 (95% CI 1.09 to 1.80)
to RR 1.48 (95% CI 1.12 to 1.94); P = 0.005 (heterogene-
ity: tau
2 = 0.061; I
2 = 55.5%, P = 0.047). For the subgroup
of acute MI patients, the RR increases from 1.23 (95% CI
0.89 to 1.69) to RR 1.32 (95% CI 0.86 to 2.04); P = 0.204
(heterogeneity: tau
2 = 0.075; I
2 = 75.7%, P = 0.043).
Lastly, we also calculated prediction intervals, which
are wider compared to confidence intervals. For the
overall results, including all studies, the RR was 1.40
with a prediction interval of 0.70 to 2.78. For the
patients with elective PCI, it was 1.64 (0.47 to 5.65), for
those with acute MI it was 1.23 (0.04 to 38.11).
This means that we predict that the true effect in a
new study (assumed to be ‘similar’ to those studies
included in the meta-analysis) would lie between RR =
0.70 and RR = 2.78 with 95% confidence. As such,
although the average effect across studies of a 40%
increase in restenosis in patients with a good collaterali-
zation is statistically significant, due to unexplained het-
erogeneity between existing results we cannot be sure of
an effect in a new study.
Figure 2 Forest plot of risk ratios (RR) for restenosis (≥ 50% diameter stenosis). Markers represent point estimates of risk ratios, marker size
represents study weight in random effects meta-analysis. Horizontal bars indicate 95% confidence intervals. CCC, coronary collateral circulation;
CI, confidence interval.
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This meta-analysis of seven studies shows that a ‘good
collateralization’ is predictive for restenosis in patients
undergoing PCI. This risk was found to be increased by
4 0 %( 9 5 %C I0 %t o8 0 % )c o m p a r e dt op a t i e n t sw i t h
poor collateralization. This association was found to be
stronger in patients with stable coronary artery disease
(risk increased by 64% (14% to 135%)) while it was
weaker for patients with acute MI (risk increased by
23% (-11% to 69%)) and did not reach statistical signifi-
cance in this subset. It has to be considered that the dif-
ferences of the RR estimates between these subgroup
analyses were not statistically significant. Moreover, all
these values are estimates of the average effect across
the different studies.
This data indicate that the degree of collateralization
may be a useful and simple tool to inform individual
clinical decision making, patients at high risk for reste-
nosis may profit from the more expensive drug-eluting
stents and from cilostazol, which both reduce the reste-
nosis risk [27,28].
Collaterals: good or bad?
Good coronary collateralization has been found to be
associated with improved survival [3,4,29]. In this regard
it may seem contradictory that good collateralization is a
risk factor for restenosis after PCI. Similarly, accelerated
disease progression of the native vessel after coronary
artery bypass grafting (CABG) is a frequent phenomenon
that does not affect the clinical benefit of CABG [30].
Coronary collaterals may be regarded as an analog to
CABG in that both provide an alternative blood supply to
the myocardium. Therefore, increased restenosis after PCI
and improved survival benefit in patients with good col-
lateralization are not mutually exclusive. Restenosis is
usually a slow process and rarely results in a life-threaten-
ing event. This is demonstrated by the fact that most treat-
ments that reduce the risk for restenosis, for example,
drug eluting stents, do not result in improved survival.
Potential mechanisms
One of the possible reasons for the increased risk of
restenosis in case of a good collateralization is the flow
Figure 3 Forest plot of risk ratios (RR) for restenosis (≥ 50% diameter stenosis), stratified by measurement method (CFI-based versus
visual collateral assessment). Horizontal bars indicate 95% confidence intervals. CCC, coronary collateral circulation; CFI, collateral flow index;
CI, confidence interval.
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blood flow through the native vessel [23,31,32]. As men-
tioned above, a similar phenomenon is frequently
observed in native coronary arteries in proximity to a
bypass graft, which also represents a collateral circula-
tion, leading to decreased flow through the native vessel
[31,32]. This reduced flow subsequently results in a
decreased shear stress on the endothelial cell layer. This
shear stress is known to be atheroprotective [33]. Mono-
cytes and platelets are key players in the pathogenesis of
intimal hyperplasia and atherosclerosis; low flow and
low shear stress increases the chance of cell adhesion to
the vessel walls [34]. Low shear stress also modulates
endothelial cell gene expression into a proinflammatory
state [35]. High shear stress, on the other hand, is sup-
pressing the expression of these proinflammatory genes,
specifically via the lung Kruppel-like factor (LKLF), an
anti-inflammatory endothelial transcription factor
[36,37]. LKLF also reduces the expression of the
substance monocyte chemoattractant protein 1 (MCP-
1). As its name suggests, MCP-1 attracts monocytes and
has a proatherogenic effect [38]. However, the exact
mechanism of this ‘mechanotransduction’, translating
physical forces into changes at a molecular level, is not
completely understood. Dat as u g g e s tt h a tGp r o t e i n s
may act as primary mechanosensors on endothelial cells;
a further concept that has evolved are mechanosensitive
ion channels that translate the physical force into a cor-
responding intracellular signal [39].
Coronary collaterals as a marker or as a causal risk factor
for restenosis?
The major determinant of collateral function is the
degree of vessel stenosis, which itself has been described
to increase restenosis risk [40-42]. The studies included
in this meta-analysis did not adjust for covariates such
as vessel diameter stenosis or the extent of CAD. As an
alternative explanation, coronary collaterals could simply
Figure 4 Forest plot of risk ratios (RR) for restenosis (≥ 50% diameter stenosis), stratified by clinical setting (stable CAD versus acute
MI). Horizontal bars indicate 95% confidence intervals. CAD, coronary artery disease; CCC, coronary collateral circulation; CFI, collateral flow index;
CI, confidence interval; MI, myocardial infarction.
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Page 7 of 11Figure 5 Influence analysis with forest plot of risk ratios (RR) for restenosis. Each line represents a reanalysis of the data with exclusion of
one study (inclusion of six studies only) at a time to assess the influence of this particular study on the overall result.
Figure 6 Funnel plot of the estimates of relative risk versus standard error. Lower standard errors indicate better precision and larger
study size. SE, standard error.
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consecutive increased risk for restenosis after PCI. This
interesting question remains to be resolved in future
studies. Regardless of a causal or a casual association,
the degree of coronary collateralization represents a
valuable and simple marker to predict the risk for
restenosis.
Outlook
Future research should evaluate possible mechanisms of
this increased restenosis risk in patients with good col-
lateralization. This patient group may show different
levels of cytokine activation, inflammation, levels of
reactive oxygen species (ROS) or platelet activation after
percutaneous transluminal coronary angioplasty
(PTCA), which may be addressed by additional pharma-
cologic approaches. One hypothesis to be tested is that
the oxygen level distal to the vessel occlusion during
angioplasty varies with varying collateralization and may
lead to different ROS levels. Higher ROS levels may
damage endothelial cells downstream and thereby
increase the risk for restenosis.
Limitations of this meta-analysis
Most studies used exclusively binary data for their ana-
lysis. The extent of variable of interest, collateralization,
was dichotomized into ‘good collateralization’ and ‘poor
collateralization’, while in fact the degree of collaterali-
zation is a continuous variable. Besides this variable of
interest, the outcome was also dichotomized in most
studies, using a restenosis threshold of 50%. One draw-
back of this approach is the impaired statistical power.
Still, this meta-analysis was large enough to detect a sig-
nificant influence of collaterals on restenosis risk. A
related problem is the fact that all patients underwent
routine angiographic follow-up. Some of the patients
may have had a stable in-stent restenosis without symp-
toms, the routine angiographic follow-up may overrate
the clinical importance of restenosis and it may overesti-
mate the impact of collaterals on restenosis [43].
Further, the included studies did not adjust for poten-
tial confounding factors such as the severity of CAD,
the diameter stenosis, and so on. Since this is a study-
level and not a patient-level meta-analysis, we were not
able to include these factors in our analyses. However,
we think that significant confounding regarding our pri-
mary outcomes is rather unlikely. The main determinant
of collaterals (our predictor) is the degree of the vessel
diameter stenosis; the narrower the stenosis, the better
the collaterals [40]. However, the degree of stenosis is
not known to be a risk factor for future restenosis (pri-
mary outcome of our study).
Moreover, this study does not capture the dynamic of
the coronary collaterals. The coronary collateral
function has been demonstrated to decrease over a 6-
month period after PCI [44]. This dynamic may explain
the non-significant results in the setting of acute MI.
During an acute vessel occlusion, the collaterals undergo
rapid changes; a fact, that limits the value of a single
timepoint measurement. Further, the increased left ven-
tricular end diastolic pressure during acute MI impairs
the accuracy of the collateral assessment [26].
Another important limitation is the heterogeneity
among the studies included in this analysis. The extent
of heterogeneity reduces the robustness of our results.
We therefore performed several subset analyses and
meta-regression analysis, and found several aspects that
contribute to this heterogeneity. The most important
one is the difference in study populations. Four studies
included patients with stable CAD while three studies
focused on patients with acute MI (Table 2). Further,
the earliest two studies used plain balloon angioplasty
while the newest studies used bare metal stents in all
patients [5,24]. Also, four studies used CFI-based collat-
eral assessment while three studies used visual assess-
ment of collaterals. Despite this heterogeneity between
studies, the findings were very consistent in most of the
subset and sensitivity analyses. Moreover, the accuracy
of CFI measurements in the setting of acute MI has
been questioned [26]. However, this only applies to one
study [6] and excluding this study only minimally influ-
enced the overall results (see ‘Sensitivity analyses’).
A further drawback of this study is that early studies
used plain balloon angioplasty and later studies used
BMS. No drug-eluting stents (DES) were used in the
present studies. Whether the results of this meta-analy-
sis can be generalized to DES remains unanswered. DES
have further reduced the risk for restenosis; it is highest
for POBA (32% in average), around 22% for BMS and
around 16% for first-generation DES [45,46]. The pre-
dictive value of collaterals may be reduced in the con-
text of DES. However, even with DES, restenosis is still
a significant and unresolved problem. Our findings were
consistent in the POBA and in the BMS group; they
were not significantly influenced by the proportion of
BMS use in the individual studies or by the average rest-
enosis risk in the control groups (poor collaterals). We
would therefore expect similar results for drug-eluting
stents.
Another limitation of our study is that it does not
provide further insights into possible causal mechanisms
of our findings. Our considerations in the Discussion
are thus rather hypothetical. This study, overall, is
hypothesis generating rather than confirmatory.
With regard to the meta-regression analyses, it has to
be considered that they have limited statistical power
and a lack of statistical significance does not necessarily
mean that there is no true effect.
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The results of this meta-analysis including 1,425 patients
show that a good coronary collateralization indicates an
increased risk for restenosis. The degree of coronary
collateralization may be useful information for clinical
decision making during PCI, such as stent choice (DES
versus BMS) and use of cilostazol, and it may also
impact the aggressiveness of the post-PCI management.
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